Last €0.88 EUR
Change Today +0.012 / 1.39%
Volume 0.0
C5V On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 2:20 AM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

cardica inc (C5V) Snapshot

Open
€0.84
Previous Close
€0.87
Day High
€0.88
Day Low
€0.84
52 Week High
08/13/13 - €1.08
52 Week Low
04/15/14 - €0.59
Market Cap
78.1M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
88.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CARDICA INC (C5V)

Related News

No related news articles were found.

cardica inc (C5V) Related Businessweek News

No Related Businessweek News Found

cardica inc (C5V) Details

Cardica, Inc. designs, manufactures, and markets automated anastomotic systems for use by cardiac surgeons to perform coronary bypass surgery in the United States and internationally. It provides C-Port Distal Anastomosis systems, including C-Port xA Anastomosis systems to perform an end-to-side distal anastomosis by attaching the end of a bypass graft to a coronary artery downstream of an occlusion or narrowing; C-Port Flex A Anastomosis systems to enable automated anastomoses to be performed as part of coronary artery bypass grafting procedures; and PAS-Port Proximal Anastomosis systems to perform an end-to-side proximal anastomosis between a saphenous vein and the aorta. The company markets its Port Distal Anastomosis systems through its direct sales force, as well as through independent manufacturers’ representatives and distributors. It is also involved in the development of endoscopic microcutter products comprising MicroCutter XCHANGE 30, a cartridge based microcutter device; MicroCutter XCHANGE 45, a planned cartridge based microcutter device; MicroCutter XPRESS 30, the true multi-fire endolinear stapling device; MicroCutter FLEXCHANGE 30 a planned cartridge based microcutter device to facilitate endoscopic procedures requiring cutting and stapling; MicroCutter XPRESS 45, a planned multi-fire endolinear microcutter device; and MicroCutter XPRESS 60, a planned cutting and stapling device for the bariatric and thoracic surgery markets. In addition, the company licenses its intellectual property in the robotics field in diagnostic or therapeutic medical procedures. The company was formerly known as Vascular Innovations, Inc. and changed its name to Cardica, Inc. in November 2001. Cardica, Inc. was founded in 1997 and is headquartered in Redwood City, California.

66 Employees
Last Reported Date: 05/7/14
Founded in 1997

cardica inc (C5V) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $381.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $280.0K
Vice President of Operations
Total Annual Compensation: $254.3K
Vice President of Research & Development
Total Annual Compensation: $275.4K
Compensation as of Fiscal Year 2013.

cardica inc (C5V) Key Developments

Cardica Announces Data Presentation at Amazing Technologies Session of 14th Annual World Congress Of Endoscopic Surgery

Cardica Inc. announced that Dr. Stefanos Demertzis, associate professor at the University of Berne, Switzerland and senior staff cardiac surgeon and deputy head of the department of cardiac surgery at the Cardiocentro Ticino Lugano, completed a study that demonstrated that there was no difference in the chronic healing response between the innovative D-shaped staple design of the Cardica five-millimeter MicroCutter XCHANGE(R) 30 and the B-shaped staple design used in conventional 12-millimeter surgical staplers. The results of the study, entitled 'Beyond the 'B': A New Concept of the Surgical Staple Enabling Miniature Staplers,' were presented by Dr. Lee Swanstrom, chief innovations officer at the University of Strasbourg's University Hospitals Institutes, clinical professor of surgery for Oregon Health and Sciences University and medical director of Cardica, as part of the Amazing Technologies Session at the 14(th) Annual World Congress of Endoscopic Surgery in Paris, France, a meeting hosted by the European Association for Endoscopic Surgery (EAES) in conjunction with the SFCE (Societe Francaise de Chirurgie Endoscopique) and the International Society for Laparoscopic ColoRectal Surgery (ISLCRS). The study compared the standard B-form staple, used in conventional 12-millimeter surgical staplers, to the innovative D-shaped staple used in the Cardica MicroCutter XCHANGE 30, the world's first and only five-millimeter surgical stapler that articulates to 80 degrees. Chronic histology performed showed that the D-shaped staple elicited a normal healing response with minimal inflammation and lack of excessive scar tissue formation. Further, there was no difference in the chronic healing response between 'D' and 'B' shaped staples.

Cardica Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2014

Cardica Inc. reported earnings results for the third quarter and nine months ended March 31, 2014. Net loss for the third quarter ended March 31, 2014 was $4.38 million, or $0.09 loss per share, compared to a net loss of $3.95 million, or $0.1 loss per share, for the same quarter ended March 31, 2013. Total revenue for the third quarter ended March 31, 2014 was $934,000, compared to $868,000 for the same quarter ended March 31, 2013. Net loss for the nine months ended March 31, 2014 was $12.29 million, or $0.24 loss per share, compared to a net loss of $12.28 million, or $0.33 loss per share, for the same period ended March 31, 2013. Total revenue for the nine months ended March 31, 2014 was $2.59 million, compared to $2.63 million for the same period ended March 31, 2013.

Cardica Inc. Announces Unaudited Earnings Results for Third Quarter and Nine Months Ended Mar. 31, 2014

Cardica Inc. announced unaudited earnings results for third quarter and nine months ended Mar. 31, 2014. For the quarter, the company reported revenue of $934,000, loss from operations of $4,254,000, net loss of $4,379,000 or $0.09 basic and diluted per share compared to the revenue of $868,000, loss from operations of $3,836,000, net loss of $3,946,000 or $0.1 basic and diluted per share, for the same quarter a year ago. For the year to date, the company reported revenue of $2,590,000, loss from operations of $11,953,000, net loss of $12,290,000 or $0.24 basic and diluted per share compared to the revenue of $2,627,000, loss from operations of $11,950,000, net loss of $12,278,000 or $0.33 basic and diluted per share, for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
C5V:GR €0.88 EUR +0.012

C5V Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cytori Therapeutics Inc $2.06 USD -0.06
Pluristem Therapeutics Inc $2.85 USD -0.049
Stereotaxis Inc $3.24 USD -0.05
Uroplasty Inc $2.48 USD -0.06
Vision Sciences Inc/DE $1.05 USD 0.00
View Industry Companies
 

Industry Analysis

C5V

Industry Average

Valuation C5V Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 28.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDICA INC, please visit www.cardica.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.